Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk contents
- Overview of the human complement system
- Coagulation cascade and complement cascade
- The complement and hemolytic anaemia
- Classification of hemolytic anaemias (1)
- Classification of hemolytic anaemias (2)
- Anaemias and intravascular hemolysis
- Why does the complement cause disease?
- Abrupt massive activation of complement
- Complement is activated ‘illegitimately'
- Complement-mediated hemolysis (1)
- Complement-mediated hemolysis (2)
- Complement-mediated hemolysis (3)
- A pathological process & regulatory mechanisms
- Possible role of complement in malaria
- Levels of the C3 complement in malaria
- Genetically defective regulation (inherited)
- Role of complement in different conditions
- Complement in the pathogenesis of Shiga toxin
- Clinical course of a patient with aHUS
- Genes with known mutations causative of aHUS
- Defective complement regulation in aHUS
- Genetic heterogeneity of aHUS
Topics Covered
- Overview of the human complement system
- Coagulation cascade and complement cascade
- The complement and hemolytic anaemias
- Anaemias and intravascular hemolysis
- Complement-mediated hemolysis
- Possible role of complement in malaria
- Genetically defective regulation (inherited)
- Role of complement in different conditions (Shiga toxin & aHUS)
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Luzzatto, L. (2017, June 29). Complement in PNH and other hemolytic anaemias 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/XNRX9776.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Lucio Luzzatto has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Complement in PNH and other hemolytic anaemias 1
Published on June 29, 2017
30 min
Other Talks in the Series: The Complement System
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Lucio Luzzatto,
I am an Hematologist at
Muhimbili University of Health and Applied Sciences in Dar-es-Salaam, Tanzania.
I was asked to discuss with you the role of complement in hemolytic anaemias.
0:18
I will start with other hemolytic anaemias and then I will
continue with Paroxysmal Nocturnal Hemoglubinuria or PNH,
a disease on which I've worked on for many years,
and in which the role of complement is particularly prominent and also
important because it has been the target of a new form of therapy.
0:43
I will not discuss in detail
the complement system which is illustrated here in this pathway.
I would only like to point out a few items.
First of all, complement can be activated through
different mechanisms which are referred to as the classic pathway,
the alternative pathway based on bacterial life of polysaccharide,
and the alternative pathway based on spontaneous hydrolysis of C3.
Also, please note that,
what is in black are the activation pathways,
what is in red are the inhibitory elements in the complexity of the system.
This is very, very important because complement must
be activated very efficiently when needed,
but it must be all the time regulated,
lest it goes out of hand.
So, these three pathways, one,
two and three, they all converge on one component called C5,
that is hydrolyzed by what is called the C5 convertase,
of which there are two types,
one produced by the alternative pathways and the other produced by the classic pathway.
And once we are there,
then C5 is cleaved,
and that precipitates what we call,
the distal pathway of complement.
Eventually, the formation of the membrane attack complex
which can lyse bacterial cells and God forbid,
can also lyse human cells.
And that is the basis of many of the diseases in which complement plays a role.
The only other point I'd like to particularly bring to your attention is this,
the alternative pathway shown here called
spontaneous C3 hydrolysis means that at a low rate,
the complement is activated all the time.
But when an antigen-antibody reaction takes place here then C1q is recruited,
the classic pathway starts.
And this can work at about thousand times
faster than the spontaneous complement activation.
But the spontaneous complement activation means that all the time,
the complement must be regulated in order,
as I said before, to avoid mischief.
The biochemical basis of these, what are being called pathways but
also being called cascades, is in general and that there are enzymatic reactions.
For instance, it is an enzymatic reaction that produces the convertase,
but the convertase in turn is an enzyme which cleaves C5.
So, what was a substrate is cleaved and becomes an enzyme and then,
what was the substrate is cleaved and does something else.